The Top 5 Biosimilars Articles for the Week of January 22

January 26, 2018

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 22, 2018.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 22.

Number 5: On the same day that its patent covering infliximab was ruled invalid, Johnson & Johnson revealed that biosimilar competition has led to a substantial drop in sales of Remicade.

Number 4: Newly published results of a survey of physicians show that some data that physicians would like to see demonstrated in bioequivalence studies may not be feasible in clinical trials.

Number 3: The European Medicines agency is asking pharmaceutical companies to report on how prepared they are for Brexit.

Number 2: A report from Trinity Partners points to complex pricing, legal and promotional issues, and a lack of biosimilar interchangeability as 3 key reasons for slow US biosimilar uptake.

Number 1: Pfizer has released positive top-line data for its proposed rituximab biosimilar in a phase 3 clinical trial.

Finally, last week, our e-newsletter asked whether biosimilars will be used in off-label indications in the same way that their reference products often are. To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.